Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Drug delivery describes the method and approach to delivering drugs or pharmaceuticals and other xenobiotics to their site of action within an organism, with the goal of achieving a therapeutic outcome. Issues of pharmacodynamics and pharmacokinetics are important considerations for drug delivery.
Releasing prodrugs through nitroreduction is a promising strategy in cancer treatment. In this study, the authors present a 4,4‘-bipyridine-mediated bioorthogonal aromatic nitro reduction for activation of nitro prodrugs.
Cancer immunotherapy leans on the effective activation on immune response within tumors and surrounding immunosuppressive microenvironment. Here, the authors report a triblock copolymeric nanocarrier encapsulating Resiquimod for B16F10 cell-targeting, which enables in situ tumor vaccination and tumor-associated macrophages polarization.
Amine headgroups in ionizable lipids drive the immunogenicity of lipid nanoparticles by binding to Toll-like receptor 4 and CD1d and by promoting lipid-raft formation.
A DNA origami nanodevice presents its hidden death ligand pattern in the acidic tumour microenvironment to kill cancerous cells, opening opportunities for effective and safe cancer therapy.
We have developed a versatile approach for promoting the penetration of commensal bacteria into the intestinal mucosa, by coating the bacterial surface with poly(ethylene glycol) (PEG). PEGylation-enabled penetration facilitated the preferential localization of bacteria at the mucus layer of the intestinal mucosal barrier, thereby reinforcing this barrier.
The oral delivery of difficult-to-drug molecules, such as peptides, can be achieved using milk-derived extracellular vesicles. The Tiny Cargo Company has established a workflow for the large-scale production of extracellular vesicles from milk for the development of XoLacta — an oral therapy that mitigates the side effects of radiation therapy.
